Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study

This study investigates a treatment called DEB-BACE, which uses tiny beads loaded with medication to block blood supply to lung tumors and deliver chemotherapy directly to the tumor site. The goal was to see if this treatment could help people with non-small cell lung cancer that hasn't responded to other treatments, and whether it could improve their quality of life. Researchers followed patients over time to track survival rates, tumor response, and any side effects from the treatment.

• 1
  DEB-BACE was effective in treating refractory NSCLC, with an overall response rate (ORR) of 88.37% and a disease control rate (DCR) of 95.35% after 2 months.
• 2
  The median overall survival (OS) was 11.5 months, and the 3-, 6-, 12-, and 24-month survival rates were 100%, 86.0%, 41.9%, and 11.8%, respectively.
• 3
  Patients experienced significant improvements in quality of life, including improvements in physical and emotional functions, as well as reduced fatigue, nausea, vomiting, dyspnea, and insomnia.